Cargando…
Embolization with MVP (Micro Vascular Plug(®)): experience on 104 patients in emergent and elective scenarios
AIM: To describe a 3 years experience of peripheral arterial embolization with Micro Vascular Plug (MVP) (Medtronic, USA). MATERIALS AND METHODS: The following parameters were investigated: type of vascular injury, anticoagulation therapy at time of procedure, anatomical district, caliper of the tar...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273051/ https://www.ncbi.nlm.nih.gov/pubmed/34250548 http://dx.doi.org/10.1186/s42155-021-00246-2 |
_version_ | 1783721305466470400 |
---|---|
author | Giurazza, Francesco Ierardi, Anna Maria Contegiacomo, Andrea Corvino, Fabio Carrafiello, Giampaolo Niola, Raffaella |
author_facet | Giurazza, Francesco Ierardi, Anna Maria Contegiacomo, Andrea Corvino, Fabio Carrafiello, Giampaolo Niola, Raffaella |
author_sort | Giurazza, Francesco |
collection | PubMed |
description | AIM: To describe a 3 years experience of peripheral arterial embolization with Micro Vascular Plug (MVP) (Medtronic, USA). MATERIALS AND METHODS: The following parameters were investigated: type of vascular injury, anticoagulation therapy at time of procedure, anatomical district, caliper of the target artery, course of the landing zone, additional embolics, technical and clinical success, device related clinical complications. Technical success was defined as complete embolization without deployment of additional embolics after MVP release. Primary clinical success was considered as hemodynamic stability in emergency setting and resolution of the underlying vascular pathology in elective cases; secondary clinical success was considered clinical success after a second embolization session. RESULTS: 116 MVP have been released in 104 patients (67 males and 37 females; mean age 61.3 years). The pullback release technique was adopted in each case. 85 patients were treated in emergent settings while in 19 patients the procedure was scheduled. The overall technical success was 75%. Primary clinical success was 96.1%, secondary clinical success 3% and clinical failure 0.9%. No statistical differences in terms of effectiveness were observed among patients assuming anticoagulation (p-value = 0.6). A straight and longer landing zone were statistically associated with higher technical success compared to curved and shorter ones, (p-values < 0.001 and = 0.048 respectively). MVP-3 and MVP-5 were the most frequently adopted models in this sample, in 29.8% and 49% of the patients respectively. No clinically adverse events directly related to MVP occurred; in 3 cases device migration was registered without clinical complications. CONCLUSION: MVP is a safe and effective embolic agent. While eventual concomitant anticoagulation therapy did not influence the technical outcome, straight course and length of the landing zone are essential parameters to evaluate before deployment. |
format | Online Article Text |
id | pubmed-8273051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-82730512021-07-20 Embolization with MVP (Micro Vascular Plug(®)): experience on 104 patients in emergent and elective scenarios Giurazza, Francesco Ierardi, Anna Maria Contegiacomo, Andrea Corvino, Fabio Carrafiello, Giampaolo Niola, Raffaella CVIR Endovasc Original Article AIM: To describe a 3 years experience of peripheral arterial embolization with Micro Vascular Plug (MVP) (Medtronic, USA). MATERIALS AND METHODS: The following parameters were investigated: type of vascular injury, anticoagulation therapy at time of procedure, anatomical district, caliper of the target artery, course of the landing zone, additional embolics, technical and clinical success, device related clinical complications. Technical success was defined as complete embolization without deployment of additional embolics after MVP release. Primary clinical success was considered as hemodynamic stability in emergency setting and resolution of the underlying vascular pathology in elective cases; secondary clinical success was considered clinical success after a second embolization session. RESULTS: 116 MVP have been released in 104 patients (67 males and 37 females; mean age 61.3 years). The pullback release technique was adopted in each case. 85 patients were treated in emergent settings while in 19 patients the procedure was scheduled. The overall technical success was 75%. Primary clinical success was 96.1%, secondary clinical success 3% and clinical failure 0.9%. No statistical differences in terms of effectiveness were observed among patients assuming anticoagulation (p-value = 0.6). A straight and longer landing zone were statistically associated with higher technical success compared to curved and shorter ones, (p-values < 0.001 and = 0.048 respectively). MVP-3 and MVP-5 were the most frequently adopted models in this sample, in 29.8% and 49% of the patients respectively. No clinically adverse events directly related to MVP occurred; in 3 cases device migration was registered without clinical complications. CONCLUSION: MVP is a safe and effective embolic agent. While eventual concomitant anticoagulation therapy did not influence the technical outcome, straight course and length of the landing zone are essential parameters to evaluate before deployment. Springer International Publishing 2021-07-12 /pmc/articles/PMC8273051/ /pubmed/34250548 http://dx.doi.org/10.1186/s42155-021-00246-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Giurazza, Francesco Ierardi, Anna Maria Contegiacomo, Andrea Corvino, Fabio Carrafiello, Giampaolo Niola, Raffaella Embolization with MVP (Micro Vascular Plug(®)): experience on 104 patients in emergent and elective scenarios |
title | Embolization with MVP (Micro Vascular Plug(®)): experience on 104 patients in emergent and elective scenarios |
title_full | Embolization with MVP (Micro Vascular Plug(®)): experience on 104 patients in emergent and elective scenarios |
title_fullStr | Embolization with MVP (Micro Vascular Plug(®)): experience on 104 patients in emergent and elective scenarios |
title_full_unstemmed | Embolization with MVP (Micro Vascular Plug(®)): experience on 104 patients in emergent and elective scenarios |
title_short | Embolization with MVP (Micro Vascular Plug(®)): experience on 104 patients in emergent and elective scenarios |
title_sort | embolization with mvp (micro vascular plug(®)): experience on 104 patients in emergent and elective scenarios |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273051/ https://www.ncbi.nlm.nih.gov/pubmed/34250548 http://dx.doi.org/10.1186/s42155-021-00246-2 |
work_keys_str_mv | AT giurazzafrancesco embolizationwithmvpmicrovascularplugexperienceon104patientsinemergentandelectivescenarios AT ierardiannamaria embolizationwithmvpmicrovascularplugexperienceon104patientsinemergentandelectivescenarios AT contegiacomoandrea embolizationwithmvpmicrovascularplugexperienceon104patientsinemergentandelectivescenarios AT corvinofabio embolizationwithmvpmicrovascularplugexperienceon104patientsinemergentandelectivescenarios AT carrafiellogiampaolo embolizationwithmvpmicrovascularplugexperienceon104patientsinemergentandelectivescenarios AT niolaraffaella embolizationwithmvpmicrovascularplugexperienceon104patientsinemergentandelectivescenarios |